Clinical Trial Update: A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC) [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 1/2 study evaluating the combination of abemaciclib and cabozantinib in metastatic renal cell carcinoma and translo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma
• Translocation Renal Cell Carcinoma

Drugs mentioned

• Abemaciclib (Verzenio) (abemaciclib)
• Cabozantinib (Cabometyx) (cabozantinib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Metastatic Renal Cell Carcinoma, Translocation Renal Cell Carcinoma | Phase 1, Phase 2 | Status: RECRUITING